Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Invested Capital (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Invested Capital for 16 consecutive years, with $853.5 million as the latest value for Q4 2025.

  • Quarterly Invested Capital rose 17.46% to $853.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $853.5 million through Dec 2025, up 17.46% year-over-year, with the annual reading at $853.5 million for FY2025, 17.46% up from the prior year.
  • Invested Capital hit $853.5 million in Q4 2025 for Ani Pharmaceuticals, up from $822.7 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $853.5 million in Q4 2025 to a low of $222.9 million in Q3 2021.
  • Historically, Invested Capital has averaged $416.7 million across 5 years, with a median of $303.3 million in 2022.
  • Biggest five-year swings in Invested Capital: soared 11643.08% in 2021 and later tumbled 61.34% in 2025.
  • Year by year, Invested Capital stood at $296.9 million in 2021, then grew by 0.05% to $297.0 million in 2022, then decreased by 1.01% to $294.0 million in 2023, then soared by 147.16% to $726.6 million in 2024, then rose by 17.46% to $853.5 million in 2025.
  • Business Quant data shows Invested Capital for ANIP at $853.5 million in Q4 2025, $822.7 million in Q3 2025, and $318.9 million in Q2 2025.